ONCT
NASDAQOncternal Therapeutics Inc.
Latest news
25 items- PROncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its OperationsSAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1), and ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1 using the binding domain from zilovertamab. Ho'ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal will also be eligible t
- PRAlpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John HavensAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.
- PROncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SECSAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on March 17, 2025, which will remove Oncternal's securities from listing and registration on Nasdaq, and to subsequently deregister with the Securities and Exchange Commission ("SEC"). Nasdaq previously suspended the trading of Oncternal's common stock on December 3, 2024 and notified Oncternal that a Form 25 would be filed. However, as Nasdaq has not yet made the filing, Oncternal is doing so voluntarily to permit Oncternal to file a Form 15 to deregister with the SEC.
- SECOncternal Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
- SECOncternal Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
- SECSEC Form 10-Q filed by Oncternal Therapeutics Inc.10-Q - Oncternal Therapeutics, Inc. (0001260990) (Filer)
- PROncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerSAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). Based on initial pharmacokinetic results, two additional dosing cohorts with twice daily (BID) oral dosing of ONCT-534 had been incorporated in the Phase 1/2 study ONCT-534-101 (NCT05917470). Overall, fifteen patients received ONCT-534 once daily (QD) in six dosing cohorts and six patients received ONCT-534 BID in two dosing cohorts. Based on a data cut off of September 30, 2024, the BID dosing schedule was w
- SECOncternal Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
- PROncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic AlternativesSAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer, and ONCT-808, its ROR1-targeting autologous CAR T program for the treatment of patients with aggressive B-cell lymphoma, and to explore strategic alternatives. In the current study, interim Phase 1 results of ONCT-534 did not show clinically meaningful improvements of disease, including prostate-specific antigen (PSA) levels, in the 20 patients treated in eight dosing cohorts with vari
- SECSEC Form 10-Q filed by Oncternal Therapeutics Inc.10-Q - Oncternal Therapeutics, Inc. (0001260990) (Filer)
- SECOncternal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
- PROncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsNo dose-limiting toxicities or concerning side effects in our Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; 1200 mg cohort for ONCT-534 given orally once daily enrolled and treated; initial data readout expected in the third quarter of 2024Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for patients with relapsed or refractory aggressive B-cell lymphoma is open and enrolling patients; clinical data update expected in the fourth quarter of 2024Cash, cash equivalents and short-term investments totaled $21.4 million
- PROncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial ResultsSAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets close on Thursday, August 8, 2024. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company's financial results. The live webcast of the call will be available online at investor.oncternal.com and will be archived there for at least 30 days. About Oncternal TherapeuticsOncternal Therapeutics is a clinical-stage biopharmaceutical
- NEWSHC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price TargetHC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $19 price target.
- NEWSOncternal Therapeutics Completes Enrollment And Begins Dosing For Sixth Dose Cohort In Phase 1/2 Study Of ONCT-534 For Metastatic Castration-Resistant Prostate CancerPatients Receiving 1200 mg Daily Dose; Safety Review Committee Approved Higher Dose After Reviewing 600 mg Data; Initial Safety And Efficacy Update Expected In Q3 2024 Based On PSA Levels
- PROncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate CancerSAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the sixth cohort are receiving ONCT-534, the company's dual-action androgen receptor inhibitor (DAARI), at a dose of 1200 mg taken orally once each day. The decision to proceed to this higher do
- PROncternal Therapeutics to Present in JonesTrading Healthcare SummitSAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal's President and Chief Executive Officer will present at the JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California. JonesTrading Healthcare Seaside SummitPresentation Date and Time: Monday, July 15, 2024 at 2:30pm PTWebcast Registration: Link Please contact your JonesTrading institutional salesperson to participate in the event. Links to the replay will be accessible on the Events & Presentations page of th
- INSIDERSEC Form 4 filed by Director Kisner Daniel L4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
- INSIDERSEC Form 4 filed by Director Carter Michael G4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
- INSIDERSEC Form 4 filed by Director Larue William R4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
- INSIDERSEC Form 4 filed by Director Desimone Jill4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
- INSIDERSEC Form 4 filed by Director Theuer Charles4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
- INSIDERSEC Form 4 filed by Director Hale David F4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
- INSIDERSEC Form 4 filed by Director Wills Robert James4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
- INSIDERSEC Form 4 filed by Director Mazanet Rosemary4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
ONCT FAQ
7 questionsWhat does Oncternal Therapeutics Inc. do?
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in...Where does ONCT stock trade?
Oncternal Therapeutics Inc. (ONCT) is listed on NASDAQ.What sector and industry is ONCT in?
Oncternal Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Oncternal Therapeutics Inc. go public?
Oncternal Therapeutics Inc. (ONCT) completed its IPO in 2004.What are analysts saying about ONCT?
Oncternal Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from BTIG: Buy with a $500.00 price target on 2022-02-24. Recent price targets cluster around $500.00.What companies are similar to ONCT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ONCT side-by-side with any of them on Quantisnow.How can I track ONCT on Quantisnow?
Quantisnow aggregates Oncternal Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONCT to receive live email and push alerts on every new disclosure.